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Abstract
Parkinson’s disease (PD), characterized by loss of dopaminergic neurons in the substantia nigra, is a neurodegenerative
disorder of central nervous system. The present study was designed to investigate the therapeutic effect of ACS84,
a hydrogen sulfide-releasing-L-Dopa derivative compound, in a 6-hydroxydopamine (6-OHDA)-induced PD model. ACS84
protected the SH-SY5Y cells against 6-OHDA-induced cell injury and oxidative stress. The protective effect resulted from
stimulation of Nrf-2 nuclear translocation and promotion of anti-oxidant enzymes expression. In the 6-OHDA-induced PD rat
model, intragastric administration of ACS84 relieved the movement dysfunction of the model animals. Immunofluorescence
staining and High-performance liquid chromatography analysis showed that ACS84 alleviated the loss of tyrosine-
hydroxylase positive neurons in the substantia nigra and the declined dopamine concentration in the injured striatums of
the 6-OHDA-induced PD model. Moreover, ACS84 reversed the elevated malondialdehyde level and the decreased
glutathione level in vivo. In conclusion, ACS84 may prevent neurodegeneration via the anti-oxidative mechanism and has
potential therapeutic values for Parkinson’s disease.
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Introduction
Parkinson’s disease is an age-related progressive degenerative
disorder, which is associated with the loss of dopaminergic neurons
in the substantia nigra (SN) and leads to motor disorder like
bradykinesia, resting tremor, rigidity, and postural instability [1–
3]. Mitochondria dysfunction and oxidative stress are believed to
play an important role in the pathogenesis of PD [3]. To date,
Levodopa (L-Dopa) treatment is the most effective medication for
Pakinson’s disease as it compensates for the dopamine deficiency
[4]. However, L-Dopa does not arrest the progression of PD and
long term treatment induces side effects like dyskinesia [5–7] and
accelerates the neuron degeneration due to oxidative stress [8–11].
Hydrogen sulphide (H2S), an endogenous gasotransmitter, has
been recognized to have crucial physiological functions in central
nervous system. Reports have suggested that H2S is involved in
introducing long-term potentiation (LTP) [12,13], regulating
calcium homeostasis [14,15] and suppressing oxidative stress
[16,17]. Besides the physiology functions, H2S also plays
important roles in pathological processes of neurodegenerative
diseases. Our group has demonstrated that H2S is able to
attenuate neuroinflammation induced by lipopolysaccharide [18]
and amyloid-b [19], suppress oxidative stress induced by hydrogen
peroxide [20], and protect cells against cell injury induced by
neurotoxins such as rotenone [21] and 6-OHDA [22]. We and
other groups also found that intraperitoneal injection of NaHS (an
H2S donor) [23] or inhalation of H2S [24] asserted protective
effects against Parkinson’s disease animal models.
Based on these reports, it was speculated that the combination
of L-Dopa and H2S may have a potential therapeutic value
[25,26]. ACS84, as shown in Fig. 1, is a hybrid compound derived
from L-Dopa methyl ester (Fig. 1A) and ACS50 (a H2S-releasing
moiety) (Fig. 1B), which can penetrate blood brain barrier and
release H2S in cells [25]. Although the effect of ACS84 on PD is
not known yet, ACS84 and other H2S-releasing L-Dopa
derivatives have been proved to suppress neuroinflammation and
inflammation-induced cell injury, and elevate glutathione level
while inhibit monoamine oxidase B activity [25]. Further in-
vestigation also suggested that ACS84 protected cells against
amyloid b-induced cell injury via attenuation of inflammation and
preservation of mitochondrial function [27].
6-OHDA is a widely accepted experimental toxin for induction
of PD model, which selectively kills dopaminergic neurons [28].
Sharing similar structure with dopamine, it can be uptaken by
dopaminergic neurons through dopamine reuptake transporters.
6-OHDA generates reactive oxygen species (ROS) in the cells and
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finally induces oxidative stress and cell injury [29]. In this study,
we used both in vitro and in vivo models of 6-OHDA to evaluate the
therapeutic potential of ACS84 in PD treatment.
Materials and Methods
The experimental protocol was approved by the Institutional
Animal Care and Use Committee (IACUC) of National University
of Singapore. All animal works were carried out strictly in
accordance with IACUC regulations.
Chemicals and Reagents
All chemicals, antibodies for detecting tyrosine hydroxylase and
LDH assay kit were purchased from Sigma (Sigma, St. Louis,
MO). Antibodies for detecting Nrf-2 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The Glutathione Assay
Kit, TBARS Assay Kit and Superoxide Dismutase Assay Kit were
purchased from Cayman Chemical (Ann Arbor, Michigan).
ACS84 was prepared as previously described [25].
Cell Culture and Treatment
The human neuroblastoma cell line, SH-SY5Y, was obtained
from the American Type Culture Collection (Manassas, VA,
USA). Cells were maintained in Dulbecco’s modified Eagle’s
Medium (DMEM) supplemented with 10% foetal bovine serum
(FBS) and 0.05 U?mL-1 penicillin and 0.05 mg/ml streptomycin
at 37uC in a humidified atmosphere containing 5% CO2/95% air.
Cells were plated onto 96-well plates for viability tests and ROS
generation assay, or 35 mm dishes and incubated overnight.
Regular medium was replaced with low-serum medium (0.5%
FBS/DMEM) before treatment. For Nrf-2 translocation, medium
was changed to non-serum medium and incubated for another
12 h before treatment with ACS84, L-Dopa or NaHS for 1–8 h.
Cell Viability Assay
Cell viability was measured using the MTT reduction assay as
described previously [21]. At the end of each treatment, MTT was
added to each well at a final concentration of 0.5 mg?mL21 and
the cells were further incubated at 37uC for 4 h. The insoluble
formazan was dissolved in dimethyl sulphoxide. Colorimetric
determination of MTT reduction was measured at 570 nm with
a reference wavelength of 630 nm.
Lactate Dehydrogenase (LDH) Release Assay
At the end of treatment, cell culture medium was collected and
briefly centrifuged. The supernatants were transferred into wells in
96-well plates. Equal amounts of lactate dehydrogenase assay
substrate, enzyme and dye solution were mixed. A half volume of
the above mixture was added to one volume of medium
supernatant. After incubation at room temperature for 30 min,
the reaction was terminated by the addition of 1/10 volume of 1N
HCl to each well. Spectrophotometrical absorbance was measured
at a wavelength of 490 nm and reference wavelength of 690 nm.
Reactive Oxygen Species (ROS) Measurement
Formation of reactive oxygen species (ROS) was evaluated using
non-fluorescent dye 29, 79- dichlorofluorescin diacetate (DCFH-
DA), which freely penetrates cells and yields the highly fluorescent
product dichlorofluorescein (DCF) by ROS oxidation. Following
ACS84, L-Dopa or NaHS treatment, cells were rinsed with PBS
solution and incubated with Hank’s Buffered Salt Solution (HBSS)
containing DCFH-DA dye (10 mM final concentration) 30
Figure 1. Chemical structure of L-Dopa, ACS50 and ACS84. The chemical structures of (A) L-Dopa methyl ester, (B) ACS50, and (C) ACS84 are
displayed. ACS84 is a hybrid of L-Dopa methyl ester and ACS50. The dithiole-thione group in ACS50 is believed to release H2S in cells.
doi:10.1371/journal.pone.0060200.g001
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minutes in the dark. 6-OHDA was added then and fluorescence
was read immediately for 1 h, at an excitation wavelength (Ex) of
490 nm and an emission wavelength (Em) of 520 nm.
Superoxide Dismutase (SOD) Activity Determination
SOD activity was measured in cells using the Cayman Chemical
Superoxide Dismutase Assay Kit (Cayman Chemicals, Inc, Ann
Arbor, MI). Briefly, cells were sonicated in 20 mM HEPES buffer,
pH 7.2, containing 1 mM EGTA, 210 mM mannitol and 70 mM
sucrose, on ice. After centrifugation, the supernatant was collected.
Reaction was initiated by adding diluted xanthine oxidase to all
wells, and then the plate was incubated on a shaker at room
temperature for 20 min. The absorbance was read at 450 nm.
Reverse Transcription-PCR
The mRNA levels of GclGclM, HO-1 and b-Actin were
determined by two-step reverse transcription PCR. In brief, total
RNA was extracted using TRIzolH reagent (Invitrogen, Carlsbad,
CA, USA). Homogenized samples were then incubated at room
temperature for 5 min. Chloroform was added and tubes were
shaked vigorously by hand for 15 min followed by incubation for
3 min at room temperature once more. Samples were centrifuged
at 12000 g for 15 min at 4uC. Colourless upper aqueous phase
was transferred to a new tube containing isopropanol and
incubated for 10 min at 25uC followed by centrifugation at
12000 g for 10 min at 4uC. Supernatant was thrown away and
RNA pellet was washed with 70% ethanol. RNA concentration
was determined with NanoDrop Spectrophotometer (ND-1000,
NanoDrop Technology). Equal amounts of RNA samples
obtained were reverse transcribed into cDNA using iScriptTM
cDNA synthesis kit (Bio-Rad). Reverse transcription was per-
formed at 25uC (for 5 min), 42uC (for 30 min) and 85uC (for
5 min). The resulting cDNAs were PCR-amplified using Taq
DNA polymerase kit (i-DNA Biotechnology). The specific PCR
primer sequences used were as follows: GclC (forward primer 59-
TGAGATTTAAGCCCCCTCCT-39 and reverse primer 59-
TTGGGATCAGTCCAGGAAAC-39) [NM_001498.3], and
GclM (forward primer 59- TTTGGTCAGGGAGTTTCCAG-
39and reverse primer 59-ACACAGCAGGAGGCA AGATT-39)
[NM_002061.2] [30]; HO-1 (forward primer 59-CAGGCA
GAGAATGCTGAGTTC-39 and reverse primer 59- GCTTCA-
CATAGCGCTGCA-39) [NM_002133.2] [31]; and b-actin for-
ward primer (59-AAGAGAGG CATCCTCACCCT-39) and b-
Figure 2. Protective effect of ACS84 against cell injury induced by 6-OHDA in SH-SY5Y cells. (A–B): Dose dependent effects of ACS84 on
(A) cell viability and (B) LDH release in the 6-OHDA-treated (50 mM) SH-SY5Y cells. Cells were pretreated with ACS84 at different concentrations for 1 h
before the addition of 6-OHDA. The results were obtained at 12 h (MTT assay) or 6 h (LDH release assay) after the treatment with 6-OHDA. (C–D):
Effect of ACS84, L-Dopa and NaHS at 10 mM on cell viability (C) and LDH release (D) in SH-SY5Y cells treated with 6-OHDA. Data are presented as
mean 6 SEM, n = 5–9, ###P,0.001 versus control; *P,0.05, ***P,0.001 versus 6-OHDA-treated cells; {P,0.05, {{{P,0.001 versus ACS84-treated
cells.
doi:10.1371/journal.pone.0060200.g002
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actin reverse primer (59-TACATGGCTGGGG TGTTGAA-39)
[NM_001101.3] [32]. PCR conditions were set as 95oC (for
30 sec), 58oC (for 30 sec), and 72oC (for 30 sec) for 30 cycles. PCR
products were separated on a 1% agarose gel and stained with
ethidium bromide. The optical densities of the mRNA bands were
analyzed with GelDoc-It Imaging Systems.
Western Blot
For Western blot analysis, the cells were washed with ice-cold
PBS and homogenized with lysis buffer containing 150 mM NaCl,
25 mM Tris (pH7.5), 5 mM EDTA, 1% Nonidet P-40, (additional
10 mM NaF and 1 mM Na3VO4 were immediately added before
detection of phosphorylation) and protease inhibitor cocktail tablet
(Roche Diagnostics, Penzberg, Germany). The lysates were then
vigorously shaken on ice for one hour and centrifuged at 13,200 g
at 4uC for 10 min. After that, the supernatant was collected and
denatured by SDS-sample buffer. Epitopes were exposed by
boiling the protein samples at 100uC for 5 min. The protein
samples were separated by SDS-PAGE gel and subsequently
transferred onto the nitrocellulose membrane (Whatman). Mem-
branes were then blocked with 10% milk/TBST buffer for one
hour and incubated with appropriate primary antibodies at 4uC
overnight. On the second day, membranes were washed and
incubated with appropriate HRP-conjugated second antibody.
Visualization was performed using ECLH (plus/advanced chemi-
luminescence) kit (GE healthcare, UK). The density of the bands
on film was quantified by Image J software (National Institute of
Health, USA).
Nuclear and Cytoplasmic Protein Fractionation
The preparation of cytoplasmic and nuclear extracts was
performed using the Nuclear Extract kit (Active Motif) according
to manufacturer’s instruction. Briefly, cells were scraped using cell
lifter in ice-cold PBS. Cell pellet obtained after centrifugation was
re-suspended in a hypertonic buffer and incubated on ice for
10 min. After the addition of detergent, the suspension was
centrifuged. The supernatant (cytoplasmic fraction) was collected.
The remaining nuclear pellet was re-suspended in complete lysis
buffer. After vortex and centrifugation, the supernatant (nuclear
fraction) was collected.
6-OHDA Induced PD Rat Model
Male Sprague-Dawley (SD) rats (180–220 g) were anesthetized
with ketamine (75 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). After
Figure 3. Effect of ACS84 on oxidative stress induced by 6-OHDA in SH-SY5Y cells. (A) Dose dependent effect of ACS84 on ROS generation
in the 6-OHDA-treated (50 mM) SH-SY5Y cells. Cells were pretreated with ACS84 at different concentrations for 4 h. DCFDAH2 (10 mM) was given
30 min before the addition of 6-OHDA (50 mM). The results were obtained after the treatment with 6-OHDA for 1 h. (B–C) Effect of ACS84, L-Dopa and
NaHS at 10 mM on ROS generation (B) and SOD (C) in SH-SY5Y cells treated with 6-OHDA. SOD activity was measured 4 h after 6-OHDA treatment.
Data are presented as mean 6 SEM, n = 4–8, ###P,0.001 versus control; *P,0.05, **P,0.01, ***P,0.001, versus 6-OHDA-treated cells; {{{P,0.001,
versus ACS84-treated cells.
doi:10.1371/journal.pone.0060200.g003
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that, the rats were placed in a stereotaxic apparatus (Stoelting
Instruments, Wood Dale, IL, USA). 6-OHDA (8 mg 6-OHDA
hydrobromide dissolved in 4 ml sterile saline containing 0.02%
ascorbic acid) was unilaterally injected into the left striatum
(coordinates from bregma: AP, +1.0 mm; ML, +3.0 mm; DV,
24.5 mm) with a Hamilton syringe (0.46 mm in diameter, blunt
tip) at a rate of 0.5 ml per minute. The needle was left in place for
3 min and then slowly withdrawn in the subsequent two to three
minutes. Sham-operated rats were injected with 4 ml saline
containing 0.02% ascorbic acid into the left striatum and served
as controls in this study. After surgery, the rats were kept in cages
and exposed to a 12:12 h light-dark cycle with unrestricted access
to tap water and food.
Behavioural Test
Three weeks after surgery, the animals’ tendency to rotate in
response to apomorphine (0.5 mg/kg, s.c.) was tested. This test
was re-performed one week later, i.e. four weeks after surgery.
Only those rats consistently showing at least 7 turns per min in
both tests were considered as the successfully induced PD-like
model. These PD-like rats were then divided into different groups
receiving different treatments, vehicle- or ACS84- administered
group. In addition, the sham-operated rats also received vehicle
treatment. These treatments continued for another 3 weeks. The
rotational behaviour was monitored at one week interval till the
end of treatment, and the behaviour tests were conducted before
drug treatments in order to avoid disturbance. After 3 weeks of
treatment, the rats were euthanized by CO2 and brain tissues were
collected for assays.
Immunofluorescence Staining
The immunofluorescence staining was performed according to
the procedures as previously described with some modification
[23]. At the end of behavioural test, the animals were anesthetized
and perfused with sterile saline and subsequently with 4%
paraformaldehyde (PFA). After that, rats were decapitated. The
brain were then collected and immersed into 4%PFA for postfix at
4uC overnight. These brain samples were transferred into 15%
sucrose in phosphate buffered saline (PBS) overnight at 4uC and
subsequently to 30% sucrose solution till the brain sunk to the tube
Figure 4. Effects of ACS84 on the expression and translocation of antioxidant enzymes in SH-SY5Y cells. (A) Western blotting analysis
showing that treatment with ACS84 for 4 h promoted the nuclear accumulation of Nrf-2 in SH-SY5Y cells. Densitometric analysis performed by
normalizing nuclear Nrf-2 to cytosol Nrf-2 signals. Data were expressed as mean 6 SEM, *P,0.05, n = 5 (B) RT-PCR showing that ACS84 treatment
induced the mRNA expression of GclC, GclM and HO-1 after 4 h. Samples were collected from three independent experiments.
doi:10.1371/journal.pone.0060200.g004
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bottom. Thereafter, the brain were sectioned on a cryostat at
a thickness of 30 mm and mounted onto the poly-l-lysine coated
slides. These sections were stored at 270uC for further experi-
mentation.
The sections were permeabilized with 0.3% Triton X-100/PBS
for 10 min and blocked with 10% BSA in PBS for another 30 min.
After that, the sections were incubated with mouse monoclonal
anti-TH antibody (1:500, Sigma, St. Louis, MO, USA) for 2 h at
room temperature and followed with appropriate goat anti-mouse
secondary antibody incubation for one hour.
Lipid Peroxidation Assessment
The level of MDA, a marker of oxidative stress, was measured
using TRABS assay kit (Cayman Chemical). The assay was
performed according to the manufacturer’s instructions. In brief,
brain tissues were lyzed with chilled RIPA buffer and sonicated for
15 s at 40 V over ice. After centrifugation at 1600 g for 10 min at
4 oC, the supernatant was collected for further analysis. The
MDATBA adduct formed by the reaction of MDA in samples and
TBA supplied in the assay kit under high temperature (100 oC)
and acidic conditions. Reaction product was measured colorimet-
rically at 540 nm with a spectrophotometer (Tecan M200). The
content of MDA in samples expressed as micromolar of MDA
produced per gram of protein.
Concentration Determination of Dopamine and its
Metabolites
High-performance liquid chromatography (HPLC) was used to
detect concentration of dopamine and its metabolites in the brain
tissues. The method was described in the previous report [33]. The
striatum was sonicated in 0.1 M perchloric acid. Homogenates
were centrifuged at 14,000 g for 20min at 4251658240uC. The
supernatants were collected and adjusted the pH value around 3.
After that, the supernatants were subjected to HPLC (HTEC-500;
Eicom, Kyoto, Japan) equipped with the column (EICOMPAK
SC-3ODS; Eicom, Kyoto, Japan) and electrochemical detector
(AD Instruments Pty Ltd., Castle Hill, NSW, Australia). Data was
analyzed using PowerChrom (eDAQ, Australia).
Statistical Analysis
Statistical significance was assessed with one-way analysis of
variance (ANOVA) followed by a post hoc (Bonferroni) test for
multiple group comparison for using PASW 18 (IBM, NY). For
two group comparison, student T-test was used. Differences with p
value less than 0.05 were considered statistically significant.
Results
Protective Effect of ACS84 on 6-OHDA-induced Cell Injury
To evaluate the protective effect of ACS84 against 6-OHDA-
induced cell injury in SH-SY5Y cells, cells were pretreated with
ACS84 at different concentrations for 1 h before the treatment of
6-OHDA (50 mM) for another 6 h or 12 h. As shown in Fig. 2A
and 2B, ACS84 at 0.1 nM to 10 mM concentration-dependently
increased cell viability (Fig. 2A) and decreased LDH release
(Fig. 2B) in cells treated with 6-OHDA. As ACS84 is a compound
constituted by L-Dopa and H2S-releasing moiety, we examined
whether L-Dopa or H2S alone would be able to produce similar
protective effect as ACS84 did. As shown in Fig. 2C and 2D,
neither L-Dopa nor NaHS (an H2S donor) at the equal molar
concentration (10 mM) was sufficient to exert the similar protective
effects against 6-OHDA-induced cell injury as ACS84 did (Fig. 2C
and 2D). This is consistent with our previous findings that NaHS
produced significant protective effects only when its concentration
is higher than 100 mM [22]. These data suggest that ACS84 may
produce stronger protective effects than either L-Dopa or NaHS
alone.
ACS84 Reduced the Oxidative Stress Induced by 6-OHDA
As it was well-accepted that 6-OHDA selectively killed
dopaminergic neuron via generating reactive oxygen species
(ROS) and inducing oxidative stress in the cells, we proceeded
to examine the effect of ACS84 on 6-OHDA-induced ROS
Figure 5. Treatment with ACS84 ameliorated the rotational behaviour in the unilateral 6-OHDA-lesioned rats. ACS84 (10 mg
kg21 day21, i.g) was given daily from the 5th to 7th week after 6-OHDA lesion. Data are presented as mean6 SEM, n= 9. *P,0.05 versus the values in
Vehicle group at the corresponding time point.
doi:10.1371/journal.pone.0060200.g005
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formation in SH-SY5Y cells. As shown in Fig. 3A, ACS84 at
10 mM significantly reduced ROS production induced by 6-
OHDA (50 mM). Although NaHS also suppressed the 6-OHDA-
induced ROS formation, this effect was much weaker when
compared with that caused by ACS84 (Fig. 3B). Superoxide
dismutases (SODs) are a family of enzymes which catalyze the
dismutation of superoxide and play important roles in cell
homeostasis. As shown in Figure 3C, ACS84, but not L-Dopa
and NaHS, at 10 mM completely abolished the inhibitory effect of
6-OHDA on SOD activity.
ACS84 Promoted Anti-oxidative Stress Associated Gene
Expression
Cells express anti-oxidant enzymes to protect against oxidative
stress and most of these enzyme-coding genes contain anti-oxidant
reaction element (ARE). NF-E2-related factor 2 (Nrf-2) is an
important transcription factor which binds to ARE and initiates
the expression of anti-oxidant enzymes, including glutamate
cysteine ligase (GCL) and heme oxidase-1 (HO-1). Western
blotting analysis shows that ACS84 treatment for 4 h promoted
the nuclear translocation of Nrf-2 from cytosol to nuclear (Fig. 4A).
Figure 6. Effect of ACS84 on 6-OHDA-induced TH+ neuronal degeneration. Immunofluorescence staining showed that ACS84 (10 mg
kg21 day21, i.g) alleviated TH+ neuron loss in SN of 6-OHDA-lesioned PD rats. Photos were taken at x100 magnification, and the white bar indicated
0.1 mm. Samples were collected from two independent experiments.
doi:10.1371/journal.pone.0060200.g006
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Glutamate cysteine ligase catalytic subunit (GclC), Glutamate
cysteine ligase modifier subunit (GclM) and HO-1 are three
important Nrf-2 target genes. RT-PCR also showed that the
mRNA levels of these three genes were significantly elevated after
treatment with ACS84 for 4 h (Fig. 4B). These data suggested that
ACS84 induced Nrf-2 nuclear translocation and promoted the
expression of anti-oxidant enzymes, which contributed to the
protection against 6-OHDA-induced oxidative stress.
ACS84 Ameliorated Behaviour Symptom in the Unilateral
6-OHDA Rat Model
To evaluate the therapeutic effect of ACS84 on Parkinson’s
disease, we established the unilateral 6-OHDA lesion rat model.
Four weeks after 6-OHDA lesion, the PD rats were injected
intragastrically with vehicle or ACS84 (10 mg/kg) daily and the
treatment continued for 3 weeks. As shown in Fig. 5, ACS84
significantly ameliorated the rotation behaviour after 2 weeks of
treatment, which indicated that the administration of ACS84 may
alleviate the behaviour disorder in Parkinson’s disease.
ACS84 Attenuated the Degeneration of Dopaminergic
Neuronal in SN
The movement dysfunction of the PD model is mainly
associated with the loss of dopaminergic neurons in the SN and
striatum. From the immunostaining results (Fig. 6), unilateral 6-
OHDA lesion destroyed most of the tyrosine hydroxylase positive
(TH+) neurons in SN pars compacta in the injured hemisphere,
while the administration of ACS84 remarkably attenuated the
effects. As tyrosine hydroxylase is the rate-limiting enzyme in
dopamine synthesis, this data suggests that ACS84 may preserve
the function of dopaminergic neurons in 6-OHDA-injured.
ACS84 Relieved the Declined Dopamine Level in the 6-
OHDA-injured Striatum
We further examined the dopamine and its metabolic products
levels in the injured striatum. The concentrations of dopamine and
the dopamine metabolites, dihydroxyphenylacetic acid (DOPAC)
and homovanillic acid (HVA) were measured with HPLC. As
shown in Table 1, 6-OHDA lesion significantly decreased the
concentrations of dopamine, DOPAC and HVA in the injured
striatum, while ACS84 treatment reversed these effects. These
data were comparable with the results of behaviour test and
immunofluorescence staining, indicating that ACS84 efficiently
alleviated the loss of dopaminergic neurons and the deficient of
dopamine in the striatum. In our experiments, we observed
a significant increase of dopamine/HVA ratio but not dopamine/
DOPAC ratio in ACS84 animals compared with vehicle group,
Table 1. Effect of ACS84 on dopamine and its metabolites in 6-OHDA-lesioned striatum.
Treatment Dopamine DOPAC HVA Dopamine/DOPAC Dopamine/HVA
Sham 8.2561.01 2.5460.71 1.4760.23 4.9060.74 5.9660.46
Vehicle 1.6160.45# 1.0060.24 0.7160.10 2.0360.72# 2.2460.50#
ACS84 7.3561.62* 3.8160.89* 2.1560.41* 2.1560.41 4.9060.67*
The concentration of dopamine and its metabolites in 6-OHDA-lesioned striatum were measured using HPLC. Units for Dopamine, DOPAC and HVA concentrations were
ng/g tissue. Data are presented as mean 6 SEM, n = 6–8.
#p,0.05 versus Sham group and *p,0.05 versus Vehicle group.
doi:10.1371/journal.pone.0060200.t001
Figure 7. Effect of ACS84 on oxidative stress in the striatum of unilateral 6-OHDA-lesioned PD rat model. ACS84 treatment (10 mg
kg21 day21, i.g) alleviated the increased MDA production. Data are presented as mean6 SEM, n = 4–6. *P,0.05 versus lesion site of Sham group and
#P,0.05 versus lesion site of Vehicle group.
doi:10.1371/journal.pone.0060200.g007
Protective Effect of ACS84 a PD Model
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indicating that ACS84 might also suppress catechol-O-methyl
transferase (COMT) activity.
ACS84 Suppressed the Oxidative Stress in the Injured
Striatum
Malondialdehyde (MDA) is a marker for lipid peroxidation to
indicate the oxidative stress level in the striatum. As shown in
Fig. 7, 6-OHDA induced the elevation of MDA production in the
injured striatum, when compared to sham and healthy striatum.
ACS84 treatment significantly suppressed this effect. This data
suggested that ACS84 protected dopaminergic neurons degener-
ation by suppressing oxidative stress in the brain.
Discussion
The symptoms of Parkinson’s disease are associated with the loss
of dopaminergic neurons and the deficiency of dopamine in the
SN and striatum, and oxidative stress plays a crucial role in the
pathology of neurodegeneration [3,34]. Though the traditional L-
Dopa treatment for PD patients could compensate for the
dopamine deficiency and alleviate the behaviour disorder, long-
term usage of L-Dopa has its disadvantages and has been proven
to enhance oxidative stress [8–11].
H2S has been recognized as an anti-oxidant [20,35,36] and our
group has demonstrated the protective effect of H2S in 6-OHDA
and rotenone-induced PD models [21]. ACS84 is a hybrid
compound which is derived from L-Dopa and one H2S-releasing
moiety, ACS50 [25]. ACS84 and other H2S-releasing L-Dopa
derivatives have been shown to have therapeutic potential as they
suppressed microglia activation [25]. In the present study, we used
6-OHDA-induced PD model to investigate the therapeutic effect
of ACS84.
It is interesting to find that ACS84 showed significant protective
effect against 6-OHDA-induced cell injury and oxidative stress in
SH-SY5Y cells, while at equal molar concentration of both L-
Dopa and NaHS failed to achieve. Though it has been reported
that NaHS was able to protect the cells against apoptosis and
oxidative stress, our results suggested that ACS84 showed a better
therapeutic potential as it produced protective effect at a lower
dose, at which concentration NaHS failed to protect neuronal
cells. We postulated that the better effect of ACS84 may be due to
its slower H2S-releasing rate. In addition, ACS84 releases H2S
intracellularly by mitochondria [26]. This may further enhance
the action efficiency of endogenous H2S. Another possibility is that
the metabolites of ACS84 may interact with endogenous H2S or its
generating enzyme, cystathionine b-synthase (CBS) to produce
stronger effect than exogenous application of NaHS. More
experiments are warranted to investigate the exact underlying
mechanism.
Gcl and HO-1 are anti-oxidant enzymes involving in the
cellular stress defence system. Both coding gene contain ARE cis-
element. When activated, transcript factor Nrf-2 translocates from
the cytoplasm to the nuclear and binds to the ARE. This initiates
the gene expression of anti-oxidant enzymes [37–40]. Our results
showed that ACS84 treatment induced nuclear translocation of
Nrf-2 and promoted the gene transcription of GclC, GclM and
HO-1, which further indicated that ACS84 may attenuate
oxidative stress via stimulating Nrf-2/ARE pathway to increase
anti-oxidant enzymes in the cells.
S-sulfhydration of cysteine residues in proteins has now been
recognized as one of the key mechanisms for H2S physiology [41–
45]. Tao et al proposed that cysteine residues may serve as H2S
‘‘receptors’’ in cells and H2S may attack disulfide bonds in proteins
to regulate protein functions [46]. A recently published report
indicated that H2S S-sulfhydrated Keap1 at cysteine-151, which
enhanced the release of Nrf-2 from Keap-1 and upregulated Nrf-2
activity [47]. This report was on a par with our results and
suggested that S-sulfhydration may be a potential mechanism of
ACS84 in cells.
We used unilateral 6-OHDA PD rat model to evaluate the
protective effect of ACS84 in vivo. This model is mainly designed to
study the oxidative injury in PD pathogenesis process [29]. Our
group has demonstrated that the protective effects of H2S involved
suppression of NADPH oxidase in this model [21]. In the present
study, we also found that post-treatment of ACS84 preserved TH+
neurons in SN, and maintained the dopamine levels and relieved
the movement dysfunction. These data suggest that ACS84 is of
potential therapeutic value for Parkinson’s disease. We believe that
the suppression of oxidative stress was the main mechanism in the
protective effect of ACS84. We have proven that ACS84 was
efficient in reducing ROS formation and was able to stimulate the
expression of anti-oxidant enzymes in vitro. Along with these results
obtained from SH-SY5Y cells, we also found that ACS84
treatment reversed the effect of 6-OHDA on MDA levels. Having
such an effect on the two oxidative stress indicators, these data
proved that ACS84 plays a role as an anti-oxidant in the
dopaminergic neurons. Although we found that ACS84 produced
significant anti-oxidant effect, unfortunately, we failed to find
ACS84 produced better effect against movement dysfunction in 6-
OHDA-induced PD model when compared with L-dopa (data not
shown). This result implies that ACS84 is not more efficacious to
treat PD symptoms than L-Dopa alone in our observation period
(7 weeks). Longer period observation and other animal models
may be needed in future to determine which one, ACS84 or L-
dopa, produces longer and better effects.
It was reported that ACS84 intravenous injection increased the
dopamine level in the rat brain [25]. Our results also indicated
that ACS84 elevated dopamine levels in the 6-OHDA-injured
striatum. ACS84 may increase dopamine in two aspects: firstly,
ACS84 may release L-Dopa which would be further catalysed into
dopamine by DOPA decarboxylase; secondly, ACS84 protected
dopaminergic neuron degeneration, thus alleviated dopamine
deficient.
It was reported that ACS84 and other similar H2S-releasing
compounds would inhibit the monoamine oxidase B activity in
neonatal rat striatal astroglial cell primary cultures and SH-SY5Y
cells. [25,48] We also got similar results from primary cultured
astroglial cells (data not shown). However, from our HPLC results,
we did not observe the significant decline of DOPAC/dopamine
ratio in the striatum homogenates from ACS84-treated rats. These
data may suggest that the inhibitory effects of ACS84 on
monoamine oxidase B activity were not as efficient under
physiological conditions as in cell cultures. In contrast, ACS84
significantly decreased the dopamine/HVA ratios, suggesting that
ACS84 might suppress COMT activity, which was responsible for
the dopamine-HVA and DOPAC-HVA turnover in dopaminergic
neurons.
As we found ACS84 efficacy requires a chronic administration
regimen in this study, there might be some transcriptional and
translational alterations in neurons. It was found that ACS84
attenuated the down-regulated protein expression of tyrosine
hydrolase (TH) in our PD model. In addition, the anti-oxidation-
related genes were also upregulated in cells treated with ACS84
through Nrf-2 pathway. Our data suggest that the effects of
ACS84 may result from translational alternations, despite that the
initial process of S-sulfhydration itself is reversible.
In conclusion, we have demonstrated the neuroprotective effect
of ACS84, one H2S-releasing L-Dopa derivative, in the 6-OHDA
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models of Parkinson’s disease. ACS84 suppressed 6-OHDA-
induced cell injury and ROS generation and induced anti-oxidant
enzymes expression via Nrf-2 stimulation. Moreover, ACS84 also
ameliorated the movement dysfunction and dopaminergic neuron
degeneration in unilateral 6-OHDA PD rat model by suppressing
oxidative injury. Our results imply that ACS84 has the potential to
be developed to a new drug to treat Parkinson’s disease. However,
toxic effects of ACS84 also need to be determined before any
conclusion is drawn.
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